Study of AZD5335 with itraconazole in ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests how the body handles the study drug AZD5335 when taken with itraconazole (a common antifungal). It is for people with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer who have already tried standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer that got worse during or within 6 months after a platinum chemotherapy.
- You have had at least one prior platinum chemotherapy and, if eligible, also received Avastin (bevacizumab) or a PARP inhibitor (like Lynparza).
- You are able to do daily activities with little or no help (ECOG score of 0 or 1).
- You have not had lung inflammation (interstitial lung disease) that needed steroids or oxygen, and you do not have symptoms of it now.
- You have no other serious, uncontrolled health problems in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies how well and how safely azenosertib (ZN-c3) works in people with advanced ovarian, fallopian tube, or peritoneal cancer. It may help by offering a new treatment option for cancers that don’t respond well to platinum chemotherapy (platinum-resistant).
This study tests a new drug (IMGN151) given intravenously, alone or with other therapies, for people with certain gynecologic cancers, specifically high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how well it works and what side effects might occur.
This trial tests a new drug combination (trastuzumab rezetecan plus carboplatin) with or without bevacizumab, compared to standard chemotherapy, for ovarian cancer that has come back after platinum-based treatment. It aims to see if this combination works better than the usual options.
This Phase 1/2 study tests a new AstraZeneca cancer drug (AZD5335) to see how safely it can be given and how well it works in people with advanced solid tumors. You may get it alone or with another treatment, and you’ll need to provide tumor information (sometimes including a biopsy) for study planning.
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
This trial tests a new drug called azenosertib against standard chemotherapy for ovarian, fallopian tube, or peritoneal cancer that has come back after platinum-based treatment. The drug targets a specific protein (cyclin E1) found in some tumors and may help stop cancer cells from dividing.
Hear when a new Fallopian Tube Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.